PureTech Health plc (PRTC)
| Market Cap | 512.87M |
| Revenue (ttm) | 468,000 |
| Net Income (ttm) | -82.47M |
| Shares Out | 239.42M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,789 |
| Open | 21.41 |
| Previous Close | 21.31 |
| Day's Range | 21.41 - 23.50 |
| 52-Week Range | 17.08 - 34.00 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 45.00 (+99.56%) |
| Earnings Date | Aug 28, 2024 |
About PRTC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ... [Read more]
Financial Performance
In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PRTC stock is "Buy" and the 12-month stock price forecast is $45.0.
News
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors.
PureTech to Present at CHEST 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.
PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head of Communications Bharatt Chowrira - CEO Eric Elenko - Co...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Health: Results of the Tender Offer
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.
PureTech Announces Change of Board Role
BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.
PureTech Health: Result of General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer...
PureTech Announces Annual Results for Year Ended December 31, 2023
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2023.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis.
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers.
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
BOSTON--(BUSINESS WIRE)--PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions.
PureTech Health: Repeat What Works
PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's le...
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded...
PureTech to Present at Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...